Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update
November 4, 2015 9:30 AM EST
Leerink Partners maintained a Market Perform rating and $12.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), following the company's 3Q earnings report. IRWD reported 3Q Linzess sales of ~$117m coming in modestly below Leerink's estimate of ~$121m.
Analyst Jason Gerberry commented, "IRWD reported 3Q Linzess sales of ~$117m coming in modestly... More
November 4, 2015 9:09 AM EST
Leerink affirms Ironwood Pharma (Nasdaq: IRWD) with a Market Perform rating and $12 price target following Q3 results issued Tuesday night.
Analyst Jason Gerberry commented, IRWD reported 3Q Linzess sales of ~$117 million coming in modestly below our est. of ~$121 million. The miss was modest, and we dont... More
November 3, 2015 4:23 PM EST
Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.25), $0.05 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $39.6 million versus the consensus estimate of $41.76 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
...
More
